Related Experiment Videos
Downregulation of transforming growth factor-beta1 in interferon-beta1a-treated MS patients
J D Lünemann1, O Aktas, P Gniadek
1Division of Neuroimmunology, Department of Neurology, Charité University Hospital, Berlin, Germany.
Neurology
|September 26, 2001
Abstract:
The authors report an intense downregulation of transforming growth factor-beta1 (TGF-beta1) serum levels 4 weeks from start of interferon-beta1a (IFN-beta1a) treatment at 44 microg/week in 271 patients with relapsing-remitting MS, which was still present after 1 year (p < 0.001). In line with previous data, interleukin-10 serum levels did not vary significantly. These results indicate that the immunomodulatory effects of IFN-beta might not be restricted to the postulated anti-inflammatory mechanisms and address the role of TGF-beta in the pathogenesis of MS.